article · Exploration of Targeted Anti-tumor Therapy
The abstract on record is too brief for a reliable plain-language summary, so none has been generated.
The results of this study suggest that CHD4 could be used as a complementary molecular marker to improve the diagnosis and the management of PTCs-<i>BRAF<sup>V600E</sup></i> .
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.37349/etat.2026.1002363
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
